Navigation Links
A New Way to Treat Colon Cancer?

Researchers at University of Utah’s Huntsman Cancer Institute have discovered a new target for possible future colon cancer treatments – a molecule that is implicated in 85 percent of colon cancer cases. //

By knocking out – that is, genetically disabling – a molecule called C-Terminal Binding Protein (CTBP) researchers were able to rescue zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene long have been known to initiate a series of events that cause colon polyps, which eventually become cancerous. APC mutations play a role in 85 percent of colon cancers. The new findings mean CTBP also is involved in that proportion of colon cancers.

In zebrafish, APC mutations keep the intestine from developing properly. “In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation,” says David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by marking it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell.

One function of CTBP is to turn off the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation – the function that determines what type of cell forms and how long it lives. This study observed that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been “knocked out,” retinoic acid production was restored.

Earlier studies in Jones’ lab showed that lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it’s because CTBP controls retinoic acid production,” says Jones. “Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years.”

Source-Neswise
SRM
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. New FDA Approved Drug To Treat Migraine
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Angiotensin-II-receptor blockers - Treat kidney failure
7. Cipro Has Cheaper Cousins to Treat Anthrax
8. Better Treatment for obesity
9. Gene Treatment for Heart Disease
10. Cyclosporin A Treats Leukemia Complications
11. New Way To Treat Lupus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... care retirement community, dedicated its new $11.5 million, 64-room assisted living center. After ... ceremony and ribbon cutting. , The new building provides the latest in ...
(Date:5/23/2016)... ... , ... According to an article published May 12th on the Medical Daily, as ... hygiene. The article points out that, as long as patients are brushing as they should ... frayed. Of course, these worn-out bristles won’t clean teeth and gum tissue as effectively, so ...
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory ... on September 15 and 16, 2016 in San Diego, CA. The two day ... will be one of the largest gatherings of medical device companies, suppliers, professionals and ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... May 19, 2016 A new ... Heart Failure (CHF) Treatment Devices Market - Opportunities and ... devices market would reach $14.8 billion by 2022, at ... cardioverter-defibrillator (ICDs) segment is expected to dominate the world ... North America is projected to continue ...
(Date:5/19/2016)... 2016 A new report ... Robotics and Computer-Assisted Surgery Market - Opportunities and ... robotics and computer-assisted surgery market would reach $20.5 ... the highest revenue-generating segment, accounting for nearly half ... expected to maintain its dominance throughout the forecast ...
Breaking Medicine Technology: